Ying Du
Net Worth
Last updated:
What is Ying Du net worth?
The estimated net worth of Dr. Ying Du is at least $211,014,218 as of 1 Jul 2024. He owns shares worth $38,461,901 as insider, has earned $167,032,317 from insider trading and has received compensation worth at least $5,520,000 in Zai Lab Limited.
What is the salary of Ying Du?
Dr. Ying Du salary is $1,380,000 per year as Founder, Chairperson & Chief Executive Officer in Zai Lab Limited.
How old is Ying Du?
Dr. Ying Du is 59 years old, born in 1966.
What stocks does Ying Du currently own?
As insider, Dr. Ying Du owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Zai Lab Limited (ZLAB) | Founder, Chairperson & Chief Executive Officer | 1,081,910 | $35.55 | $38,461,901 |
What does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Ying Du insider trading
Zai Lab Limited
Dr. Ying Du has made 33 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 7,013 units of ZLAB stock worth $122,573 on 1 Jul 2024.
The largest trade he's ever made was exercising 600,000 units of ZLAB stock on 6 Mar 2023. As of 1 Jul 2024 he still owns at least 1,081,910 units of ZLAB stock.
Zai Lab Limited key executives
Zai Lab Limited executives and other stock owners filed with the SEC:
- Dr. Alan Bart Sandler M.D. (68) Pres & Head of Global Devel. in Oncology
- Dr. Ying Du (59) Founder, Chairperson & Chief Executive Officer
- Mr. Frazor Titus Edmondson III (59) Chief Legal Officer & Corporation Sec.
- Mr. Ki Chul Cho (47) Chief Financial Officer
- Mr. Tao Fu (53) Chief Strategy Officer